IN THE SPOTLIGHT

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy

Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation

Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation

Continuing Zenocutuzumab Past Progression Provides Clinical Benefit in NRG1+ NSCLC

Continuing Zenocutuzumab Past Progression Provides Clinical Benefit in NRG1+ NSCLC

Zenocutuzumab: An Effective Option Beyond Progression in NRG1+ NSCLC?

Zenocutuzumab: An Effective Option Beyond Progression in NRG1+ NSCLC?

Enes Yeşilbaş Presents a MET-Amplified NSCLC Case at ASCO Molecular Tumor Board

Enes Yeşilbaş Presents a MET-Amplified NSCLC Case at ASCO Molecular Tumor Board

精准肿瘤治疗的典范:EGFR 突变型 NSCLC 治疗的快速演进与现存挑战_腾讯新闻

精准肿瘤治疗的典范:EGFR 突变型 NSCLC 治疗的快速演进与现存挑战_腾讯新闻

FDA Grants Accelerated Second Approval to Boehringer’s Zongertinib for NSCLC

FDA Grants Accelerated Second Approval to Boehringer’s Zongertinib for NSCLC